Villers-lès-Nancy, 13 May 2015 - 6:00 p.m. (CET)
PRESS RELEASE
Turnover in Q1 2015, up 5.3%*
| €m | 2015 | 2014 | Change | Restated change* |
| Turnover for Q1 2015 (unaudited) | 27.04 | 28.82 | - 6.2 % | + 5.3 % |
*Restated turnover for the "Communication services" business
On 31 March 2015, the consolidated turnover of the PHARMAGEST Group was €27.04m, down 6.2% compared to 31 March 2014, but up 5.3% restated for the "Communication Services" business which was €3.13m for Q1 2014, compared to €1K for Q1 2015.
Business update:
*Turnover for the Pharmacy France business totalled €23.64m, up by 3.4% This increase in the main and traditional activity of the PHARMAGEST Group is driven by:
-Growth in sales of configurations up by 4.7%;
-Recurring revenue (maintenance and database), up by 5.1%.
The Pharmacy France business accounted for 87.4% of the total turnover of the Pharmagest Group for Q1 2015.
*The Pharmacy business in Belgium and Luxembourg (SABCO), which posted revenue of €761K on March 31 2015, continues to be affected by its commercial transformation difficulties in 2014 and was down by 21.9% in comparison to the same period in 2014. This decline is demonstrated in particular by sales of configurations which were down by 46.1% compared to Q1 2014, while recurring revenue, whose proportion of the total revenue was 58.9%, continued to increase slightly (+1.4% compared to 31 March 2014).
On March 31, 2015, the business represented 2.8% of the total revenue of the PHARMAGEST Group.
*The Laboratories business posted turnover of €0.62m as of 31 March 2015, down by 82.3% compared to the same period in 2014. Indeed, as announced, "Communication Services" were discontinued; traditional activity (therapeutic assistance campaigns, surveys, observatories, etc.) with a high margin, was up by 63% in a particularly complex regulatory environment.
The Laboratories business accounted for 2.3% of total turnover of the PHARMAGEST Group for Q1 2015, compared to 12.2% for Q1 2014.
*The Retirement Homes Business (MALTA INFORMATIQUE) with a turnover of €1.66m, maintained an excellent level of growth of 17.2% as of March 31, 2015, compared to the same period in 2014:
-License sales increased by 11.1% and demonstrate the commercial impetus of the business;
-Recurring revenues increased by 31.2%.
This business accounted for 6.1% of the turnover of the PHARMAGEST Group as of March 31, 2015.
*The e-Health business, bolstered by the success of its innovative electronic devices, produced a good performance with a turnover of €362K, an increase of 154%.
The e-health business accounted for 1.3% of the total turnover of the PHARMAGEST Group for Q1 2015.
Outlook:
-The orders currently secured together with the business model based on the repeat sales of the PHARMAGEST Group, point to continued growth of the Pharmacy France business during Q2, close to that of Q1 2015.
-The Pharmacy Belux business, following a recent reconstruction of its commercial team, should improve its performances throughout the year.
-Management of the Retirement Homes and e-Health businesses are confident of being able to maintain a consistent level of growth in Q2 2015.
-The complex regulatory environment related to the measures included in the financing of the Social Security Act may have a slight impact on the Laboratories business.
-A new activity "Brokerage" will be launched in Q2 2015 following the creation, in January 2015, by PHARMAGEST INTERACTIVE, of a true marketplace for the financing of equipment.
Financial calendar:
-Annual Ordinary and Extraordinary General Meeting on 26 June 2015 at 5:00pm at Company headquarters in Villers-lès-Nancy. The company wishes to reiterate that it will propose payment of a dividend of €2.90 per share in respect of the 2014 financial year to shareholders at the annual Ordinary General Meeting - an increase of 16% on the previous financial year. It will also be proposed that the nominal value of the PHARMAGEST INTERACTIVE shares be divided by 5, from €1 currently, to €0.20. Therefore, the share capital will consist of 15,174,125 shares of €0.20 compared to 3,034,825 shares of €1;
-Publication of Q2 turnover on 6 August 2015;
-Publication of half-year results on 22 September 2015.
About the PHARMAGEST Group:
The PHARMAGEST Group is the French leader in information technology for pharmacies, with a 43.5% market share, 9,800 clients and more than 800 employees. Since September 2007, the PHARMAGEST Group has also been present in Northern Europe with a 12% market share in Belgium and Luxembourg through its SABCO subsidiary.
As a privileged partner to pharmacists for more than 30 years now, the PHARMAGEST Group designs innovative computer solutions for pharmacies and is developing a high-potential E-Business E-Media activity intended for laboratories.
The PHARMAGEST Group is also developing innovative new solutions for Retirement Homes (Care Comes and day centres for the elderly) through its subsidiary MALTA INFORMATIQUE.
The first Logiciel de Gestion à Portail Intégré (Integrated Portal Management Software - LGPI Global Services®), creator of value for the patient, pharmacist and laboratory, boosts sales, optimises purchases and improves patient advice. It is also the first permanent-impact medium for pharmacies that provides laboratories with a direct means of communication with the pharmacist and his or her patients.
Operating at the heart of the digital revolution that is gradually establishing itself in the daily life of healthcare professionals and patients alike, at the beginning of 2012 the PHARMAGEST Group created an e-Health business, bringing together subsidiaries DIATELIC (telemedicine and e-health solutions) and DOMEDIC EUROPE (DO-Pill SecuR(TM) intelligent pill dispenser) and KAPELSE (electronic health devices).
Listed on Euronext Paris(TM) - Compartment B
Indices: ENTERNEXT TECH 40, CAC ® SMALL and CAC ® All-Tradable by inclusion
Eligible for the Long-Only Deferred Settlement Service (SRD)
ISIN : FR 0000077687 - Reuters : PHA.PA - Bloomberg : - PMGI FP
PHARMAGEST shares are eligible for France's Equity Savings Plan intended to finance SMEs (PEA-PME)
Find out the latest news from the group at www.pharmagest.com
CONTACTS
Analyst Investor Relations:
Chief Financial Officer: Jean-Yves SAMSON
Telephone: +33(0)3 83 15 90 67 - jean-yves.samson@pharmagest.com
Press Relations:
FIN'EXTENSO - Isabelle Aprile
Telephone: +33 (0)1 39 97 61 22 - i.aprile@finextenso.fr
